Highlights
- Mivocabtagene autoleucel demonstrated significant and sustained improvement in motor function in antibody-positive stiff person syndrome (SPS) patients refractory to standard immunotherapies.
- Safety profile included manageable neutropenia and mostly low-grade cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS) that resolved without sequelae.
- Observed B-cell depletion and immune reset indicate mechanistic engagement of pathogenic B-cell populations driving SPS autoimmunity.
- This study introduces a novel immunotherapy paradigm with durable, immunomodulation-free remission potential in SPS, a disease previously lacking highly effective interventions.
Background
Specialty calculators
For clinical reference; use professional judgment.
